Musculoskeletal Disorders Therapeutics Market Research Report covers the present scenario and the growth prospects of the Musculoskeletal Disorders Therapeutics Industry for 2016-2020. Musculoskeletal Disorders Therapeutics Market, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Musculoskeletal Disorders Therapeutics globally.
For further information on this report, please visit- http://www.marketreportsworld.com/10279966
The Musculoskeletal Disorders Therapeutics Market report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Following Companies Are Key Players of the Musculoskeletal Disorders Therapeutics Market:
- Johnson & Johnson
- F. Hoffmann-La Roche
- Eli Lilly
Other Prominent Vendors of Musculoskeletal Disorders Therapeutics Market Are:
- AB Sciences
- AbGenomics International
- Akron Molecules AG
- Alder BioPharmaceuticals
“Growing focus toward abuse-resistant novel drugs will be a key trend for market growth. Drug abuse is normally seen in individuals who are on opioid therapy to treat chronic pain in musculoskeletal disorders. Pain associated with musculoskeletal disorders are among the top causes of disability worldwide. There have been many instances where pain therapeutics such as Vicodin, OxyContin, and Dilaudid have been prescribed widely. This was because of the influence of pharmaceutical companies promoting their drugs for enhanced sales. Pharma companies are under constant pressure from regulatory bodies to develop novel abuse-resistant drugs. There is an increased need among pharma and biotech companies to develop abuse-resistant medicinal products to treat musculoskeletal disorders with minimal or no abuse. Off-late, researchers, and vendors are focusing on developing abuse-resistant novel drugs.”
Ask Sample PDF of Musculoskeletal Disorders Therapeutics Market Report @ http://www.marketreportsworld.com/enquiry/request-sample/10279966
According to the Musculoskeletal Disorders Therapeutics Market report, preference for combination therapies will be a key driver for market growth. Combination therapies are preferred over monotherapies due to their improved efficacy. For instance, to treat rheumatoid arthritis, more than one of the standard DMARDs is used with or without short-term steroids. Methotrexate is given in combination with sulfasalazine or with other DMARDs. Administering a combination of anabolic and antiresorptive agents can enhance bone density and bone strength better than either agent given as a monotherapy. Clinical trials have been performed to evaluate combinations of PTH1-34 or PTH1-84 with antiresorptives, including raloxifene, alendronate, risedronate, ibandronate, zoledronic acid, and denosumab. Also, the effects of combination therapies are site dependent. The most consistent result of combining antiresorptive drugs with PTH or teriparatide is a greater hip BMD outcome compared with these drugs given as monotherapies. For instance, Pfizer’s Duavee combines conjugated estrogens with bazedoxifene to treat postmenopausal osteoporosis with few side effects.
Report also presents Geographical Segmentation analysis of Musculoskeletal Disorders Therapeutics Market of Americas, APAC, EMEA region.
For Any Query, Contact Our Expert @ http://www.marketreportsworld.com/enquiry/pre-order-enquiry/10279966
Further, the Musculoskeletal Disorders Therapeutics Market report states that multiple patent expiries will be a challenge for the market. Patent expiries result in the loss of exclusivities of the specific drug, leading to a rapid decline in its sales. Also, the entry of generic versions of the drugs will lead to further loss of revenue for drug manufacturers, hindering market growth. Branded biologics, such as Humira, Enbrel, and Remicade, are set to lose their patent exclusivities during the forecast period. For instance, Roche’s Rituxan lost its patent protection in 2013 in Europe, and is set to lose the same in December 2015 in the US. These biological products, with global sales of over $20 billion, will lose their patent protection by 2020, intensifying the competition to develop their biosimilars.
Key questions answered in Musculoskeletal Disorders Therapeutics market report:
- What will the Musculoskeletal Disorders Therapeutics market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving Musculoskeletal Disorders Therapeutics market?
- What are the challenges to Musculoskeletal Disorders Therapeutics market growth?
- Who are the key vendors in Musculoskeletal Disorders Therapeutics market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
No of Pages: 120
Price of Report: $ 2500 (Single User License)
Purchase Report @ http://www.marketreportsworld.com/purchase/10279966
About Market Reports World:
Market Reports World is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Mr. Ameya Pingaley
Market Reports World
+1 408 520 9750
Email – email@example.com